Home » Generics Safe Harbor Question Could Derail Biosimilars
Generics Safe Harbor Question Could Derail Biosimilars
Biologic drug sponsors may have a powerful weapon to block competition from cheaper biosimilars, experts say, if they can successfully argue that the generic drug law’s safe harbor from patent infringement expires the moment a drug wins regulatory approval.
Law360
Law360
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May